Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
6.51
-0.41 (-5.92%)
May 18, 2026, 4:00 PM EDT - Market closed
Solid Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
121
Market Cap
640.91M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 8.09M | -5.53M | -40.57% |
| Dec 31, 2021 | 13.62M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zevra Therapeutics | 122.29M |
| Sutro Biopharma | 99.61M |
| Crescent Biopharma | 11.88M |
| Aclaris Therapeutics | 8.37M |
| Allogene Therapeutics | 22.00K |
SLDB News
- 5 days ago - Solid Biosciences price target lowered to $16 from $17 at Wedbush - TheFly
- 5 days ago - Solid Biosciences price target raised to $18 from $17 at Piper Sandler - TheFly
- 6 days ago - Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates - GlobeNewsWire
- 7 days ago - Solid Biosciences Quarterly report: Q1 2026 - Filings
- 7 days ago - Solid Biosciences Earnings release: Q1 2026 - Filings
- 11 days ago - Solid Biosciences doses part participant in IMPACT DUCHENNE study - TheFly
- 11 days ago - Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy - GlobeNewsWire
- 17 days ago - Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire